Mark Frohlich Email
CEO . Indapta Therapeutics
Seattle & Houston,
LocationPrimary Email
How to contact Mark Frohlich
Join and see Mark's contact info for free!Current Roles
Employees:
29Revenue:
$5.4MAbout
Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.Indapta Therapeutics Address
Seattle & Houston, null
United States